Connect with us

News

Mental health hospital in York gets green light

Published

on

Plans to build a new mental health hospital in York have been given the green light by NHS bosses.

The hospital new mental health hospital, which will hold 72 beds in four 18-bed wards, will be based on the former Vickers and Bio-Rad factory site in Haxby Road, York. The facility is said to be needed following the closure of Bootham Park Hospital in 2015.

The closure of Bootham Park Hospital occurred in 2015 after Care Quality Commission (CQC) inspectors said there were serious risks to patients, along with poor hygiene and too few staff.

The closure of Bootham Park Hospital left no inpatient NHS mental health hospital service in the area for a year but patients were relocated to other facilities.

Tees, Esk and Wear Valleys NHS Foundation Trust, which is behind the plan, said it was due to be completed in 2019.

Nick Land, medical director at the Trust, said: “People across the Vale of York deserve to have access to the best possible mental health care and this includes having a state-of-the-art hospital.

“The Haxby Road site has the space and layout we need to build a purpose designed hospital, that will support 21st Century care and I’m delighted that the proposal has been given the green light.

“Although we want to make sure that people can receive the care and treatment they need at home whenever possible, it’s also important that they are able to access a bed when they need one.

“Some people were worried that we wouldn’t have sufficient beds and we have listened to their concerns.

Continue Reading
Advertisement
Join the discussion...

Leave a Reply

Your email address will not be published. Required fields are marked *

Midwifery

Royal College of Midwives to end campaign to promote ‘normal births’

Published

on

By

The Royal College of Midwives ends their campaign for “normal births” to avoid making mothers who opt for medical interventions feel like failures.

The Royal College of Midwives (RCM) has been running a continuous campaign since 2005 to encourage expectant mothers to give birth without medical interventions such as; epidurals, inductions and caesareans.

Currently, around 40% of mothers give birth without medical interventions. 20% less than 30 years ago. But experts say a significant number of these are due to the increase in more risky pregnancies.

Prof Cathy Warwick, the Chief Executive of the RCM, said;

“There was a danger that if you just talk about normal births – and particularly if you call it a campaign – it kind of sounds as if you’re only interested in women who have a vaginal birth without intervention”.

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately, that seems to be how some women feel.”

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately that seems to be how some women feel.”

Midwives, will instead, start to use the term “physiological births” to describe those without interventions.

Continue Reading

News

Pancreatic cancer patients to have routine access to life extending drug after new deal

Published

on

NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and provided more evidence on its effectiveness.

Nab-paclitaxel, also known as Abraxane, made by Celgene will be routinely available as an option for patients with pancreatic cancer that has progressed.

When Abraxane is added to a standard chemotherapy, called gemcibatine the evidence has found it extends life by an average of 2.4 months.

If other combination chemotherapy treatments are unsuitable for a patient, NICE recommends offering Abraxane instead of this standard chemotherapy on its own.

It works by blocking the action of the proteins within cancer cells that cause them to grow and divide.

NICE has reviewed its guidance from 2015 which did not recommend Abraxane for routine NHS use for not being cost-effective.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: The life expectancy of pancreatic cancer is poor, with patients usually living for only up to 6 months. It’s incredibly important that patients and families affected by this disease are able to have routine access to this life extending treatment.”

There are almost 10,000 new cases of pancreatic cancer each year in the UK, and less than 1% survive for 10 or more years.

This is a final appraisal determination for Abraxane. The company, healthcare professionals and patient/carer organisations now have until Friday 1 September to appeal the decision.

Continue Reading

Trending